Source: DiscovEx/Twitter
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • DiscovEx Resources (DCX) continued its exploration program in the December quarter with a focus across its projects
  • Work was undertaken across the Sylvania, Edjudina, Newington and Greater Duchess projects which span across Western Australia and Queensland
  • Overall, soil geochemical sampling, auger geochemistry and drilling was undertaken with work identifying anomalies and strike continuation
  • In the quarter, DiscovEx burnt through $648,000 with the majority going towards exploration and evaluation and invested $13,000 in its property, plant and equipment
  • DiscovEx ends the day 10 per cent in the green with shares trading at 1.1 cents

DiscovEx Resources (DCX) continued its exploration program in the December quarter with a focus across all its projects.

Work was undertaken across the Sylvania, Edjudina, Newington and Greater Duchess projects.

Sylvania

The Sylvania Project lies in the Pilbara Region of Western Australia and consists of seven granted exploration licences and 12 exploration licence applications.

Assay results were received from DiscovEx’s phase two infill sampling program with large-scale gold anomalies identified.

Sampling confirmed the continuity and scale of the phase one results with a peak assay of 503 parts per billion (ppb) gold from the Hilditch Prospect, 101 ppb gold from the Peak Prospect and 83 ppb gold from the Bondinis Prospect.

Further soil sampling is required to further define the prospects with exploration to continue in the next quarter.

Edjudina

The Edjudina Project lies in the southern portion of the Laverton district around 700 kilometres northeast of Perth.

Soil geochemical sampling was undertaken at the Octavia Prospect with work defining a potential strike continuation of the Celia Shear.

A total of 405 soil samples were returned with results highlighting the mineralised corridor.

Furthermore, 49 aircore, for 4403 metres, were drilled in late November to test the north-western continuation of the Celia Shear. Assays are pending.

Newington

DiscovEx completed a program of shallow geochemical auger drilling at the Newington Project which lies roughly 100 kilometres north of Southern Cross in WA.

The aim of the drilling was to detect the potential surface project of the Newfield Central and Dawsons quartz lodes by sampling beneath a thin layer of transported cover.

All up, 276 samples were taken with encouraging results returned with a 250-metre long gold anomaly defined.

Greater Duchess

DiscovEx’s joint venture partner Carnaby Resources (CNB) confirmed a major copper gold discovery at the Nil Desperandum Prospect.

Carnaby encountered encouraging results from the Queensland prospect with a best intersection of 41 metres at 4.1 per cent copper including nine metres at 10.3 per cent copper.

Finances

In the quarter, DiscovEx burnt through $648,000 with the majority going towards exploration and evaluation. The company also invested $13,000 in its property, plant and equipment.

As of December 31, DiscovEx had more than $2.65 million in total available funding, representing four quarters of use if spending levels remain the same.

DiscovEx has ended the day 10 per cent in the green with shares trading at 1.1 cents in a $28.25 million market cap.

DCX by the numbers
More From The Market Herald

" Chalice Mining (ASX:CHN) maintains strong focus on top-tier Gonneville deposit

ASX 200-listed Chalice Mining (ASX:CHN) has had a rocky day on the ASX following the release…
Credit Clear (ASX:CCR) - CEO, David Hentschke

" Credit Clear (ASX:CRR) to boost revenue by $2m with new clients

Receivables management solution provider Credit Clear (CCR) has signed two new clients which are set to boost revenue by between $1.6 million and...

" PointsBet (ASX:PBH) losses extend to $51.8m

PointsBet (ASX:PBH) has reported $51.8 million in cash outflows for its quarterly update as the company…
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…